{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T03:21:46Z","timestamp":1770434506052,"version":"3.49.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T00:00:00Z","timestamp":1157068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T00:00:00Z","timestamp":1157068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2006,9]]},"DOI":"10.3816\/ccc.2006.n.039","type":"journal-article","created":{"date-parts":[[2008,9,10]],"date-time":"2008-09-10T21:06:03Z","timestamp":1221080763000},"page":"219-223","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Hand-Foot Syndrome Variant in a Dihydropyrimidine Dehydrogenase\u2013Deficient Patient Treated with Capecitabine"],"prefix":"10.3816","volume":"6","author":[{"given":"Muhammad Wasif","family":"Saif","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aymen","family":"Elfiky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Diasio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CCC.2006.n.039_bib1","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0378-4347(97)00253-3","article-title":"Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity","volume":"696","author":"Johnson","year":"1997","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"10.3816\/CCC.2006.n.039_bib2","first-page":"359","article-title":"Is capecitabine safe in patients with gastrointestinal cancer and dihydropyrimidine dehydrogenase deficiency?","volume":"5","author":"Saif","year":"2006","journal-title":"Clin Colorectal Cancer"},{"key":"10.3816\/CCC.2006.n.039_bib3","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1200\/JCO.2001.19.8.2282","article-title":"Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study","volume":"19","author":"Hoff","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2006.n.039_bib4","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.2001.19.21.4097","article-title":"Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study","volume":"19","author":"Van Cutsem","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2006.n.039_bib5","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1200\/JCO.1998.16.11.3537","article-title":"Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors","volume":"16","author":"Meta-Analysis Group in Cancer","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2006.n.039_bib6","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/ijc.10599","article-title":"Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation","volume":"101","author":"Van Kuilenburg","year":"2002","journal-title":"Int J Cancer"},{"key":"10.3816\/CCC.2006.n.039_bib7","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0021-9258(18)65251-2","article-title":"Pyrimidine metabolism. I. Enzymatic pathways of uracil and thymine degradation","volume":"221","author":"Canellakis","year":"1956","journal-title":"J Biol Chem"},{"key":"10.3816\/CCC.2006.n.039_bib8","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0163-7258(90)90080-L","article-title":"Metabolism of pyrimidine analogues and their nucleosides","volume":"48","author":"Daher","year":"1990","journal-title":"Pharmacol Ther"},{"key":"10.3816\/CCC.2006.n.039_bib9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1172\/JCI113308","article-title":"Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity","volume":"81","author":"Diasio","year":"1988","journal-title":"J Clin Invest"},{"key":"10.3816\/CCC.2006.n.039_bib10","first-page":"2672","article-title":"Dihydropyrimidine dehydrogenase: its role in 5-fluorouracil clinical toxicity and tumor resistance","volume":"5","author":"Diasio","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CCC.2006.n.039_bib11","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/1097-0142(19910801)68:3<499::AID-CNCR2820680309>3.0.CO;2-F","article-title":"Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome","volume":"68","author":"Harris","year":"1991","journal-title":"Cancer"},{"key":"10.3816\/CCC.2006.n.039_bib12","first-page":"83","article-title":"Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy","volume":"24","author":"Morrison","year":"1997","journal-title":"Oncol Nurs Forum"},{"key":"10.3816\/CCC.2006.n.039_bib13","first-page":"181","article-title":"Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration","volume":"4","author":"Ezzeldin","year":"2004","journal-title":"Clin Colorectal Cancer"},{"key":"10.3816\/CCC.2006.n.039_bib14","first-page":"768","article-title":"Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype","volume":"8","author":"Johnson","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CCC.2006.n.039_bib15","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1200\/JCO.1994.12.11.2248","article-title":"Population study of dihydropyrimidine dehydrogenase in cancer patients","volume":"12","author":"Etienne","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2006.n.039_bib16","first-page":"325","article-title":"Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: implication for 5-fluorouracil-based chemotherapy","volume":"4","author":"Lu","year":"1998","journal-title":"Clin Cancer Res"},{"issue":"pt 2 of 2","key":"10.3816\/CCC.2006.n.039_bib17","first-page":"140b","article-title":"Tolerance of capecitabine in a patient with partial dihydropyrimidine dehydrogenase (DPD) deficiency who experienced life-threatening toxicity to 5FU","volume":"21","author":"Mininberg","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CCC.2006.n.039_bib18","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/bcr575","article-title":"25th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA, 10-14 December 2002: update on preclinical and translational research","volume":"5","author":"Head","year":"2003","journal-title":"Breast Cancer Res"},{"key":"10.3816\/CCC.2006.n.039_bib19","doi-asserted-by":"crossref","first-page":"798","DOI":"10.7326\/0003-4819-101-6-798","article-title":"Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome","volume":"101","author":"Lokich","year":"1984","journal-title":"Ann Intern Med"},{"key":"10.3816\/CCC.2006.n.039_bib20","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1002\/1097-0142(19950415)75:8<2169::AID-CNCR2820750822>3.0.CO;2-H","article-title":"Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy","volume":"75","author":"Gordon","year":"1995","journal-title":"Cancer"},{"key":"10.3816\/CCC.2006.n.039_bib21","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1136\/pgmj.66.773.242","article-title":"Palmar-plantar erythema associated with combination chemotherapy","volume":"66","author":"Pagliuca","year":"1990","journal-title":"Postgrad Med J"},{"issue":"12 suppl 14","key":"10.3816\/CCC.2006.n.039_bib22","first-page":"31","article-title":"Effect of celecoxib on capecitabineinduced hand-foot syndrome and antitumor activity","volume":"16","author":"Lin","year":"2002","journal-title":"Oncology (Williston Park)"},{"issue":"5 pt 1","key":"10.3816\/CCC.2006.n.039_bib23","doi-asserted-by":"crossref","first-page":"611","DOI":"10.7326\/0003-4819-98-5-611","article-title":"Erythema and desquamation after high-dose methotrexate","volume":"98","author":"Doyle","year":"1983","journal-title":"Ann Intern Med"},{"key":"10.3816\/CCC.2006.n.039_bib24","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1046\/j.1365-2133.1998.02487.x","article-title":"Acral erythema induced by chemotherapy with cisplatin","volume":"139","author":"Vakalis","year":"1998","journal-title":"Br J Dermatol"},{"key":"10.3816\/CCC.2006.n.039_bib25","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1078::AID-CNCR19>3.0.CO;2-T","article-title":"Cutaneous fibrosis induced by docetaxel: a case report","volume":"88","author":"Cleveland","year":"2000","journal-title":"Cancer"},{"key":"10.3816\/CCC.2006.n.039_bib26","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.2001.19.21.4097","article-title":"Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer. Results of a large phase III study","volume":"19","author":"Cutsem","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2006.n.039_bib27","first-page":"2117","article-title":"Dihydropyrimidine dehydrogenase but not thymidylate synthase expression is associated with resistance to 5-FU in colorectal cancer","volume":"45","author":"Nita","year":"1998","journal-title":"Hepatogastroenterology"},{"key":"10.3816\/CCC.2006.n.039_bib28","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1023\/A:1005808822565","article-title":"Phase I trial of uraciltegafur (UFT) plus oral leucovorin: 14-day schedule","volume":"15","author":"Pazdur","year":"1997","journal-title":"Invest New Drugs"},{"key":"10.3816\/CCC.2006.n.039_bib29","first-page":"173a","article-title":"Phase I and pharmacokinetic study of the novel oral fluoropyrimidine, S-1","volume":"18","author":"Hoff","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CCC.2006.n.039_bib30","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/S0959-8049(98)00211-1","article-title":"Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients","volume":"34","author":"Sakata","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.3816\/CCC.2006.n.039_bib31","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/jjco\/hye032","article-title":"Case report: hand-foot syndrome induced by the oral fluoropyrimidine S-1","volume":"31","author":"Elasmar","year":"2001","journal-title":"Jpn J Clin Oncol"},{"key":"10.3816\/CCC.2006.n.039_bib32","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00280-003-0613-0","article-title":"Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule","volume":"52","author":"Guo","year":"2003","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.3816\/CCC.2006.n.039_bib33","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ejca.2003.12.004","article-title":"Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluouracil","volume":"40","author":"van Kuilenburg","year":"2004","journal-title":"Eur J Cancer"},{"issue":"suppl 1","key":"10.3816\/CCC.2006.n.039_bib34","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.ejon.2004.06.006","article-title":"Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda)","volume":"8","author":"Marse","year":"2004","journal-title":"Eur J Oncol Nurs"},{"key":"10.3816\/CCC.2006.n.039_bib35","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF00216925","article-title":"Pyridoxine therapy for palmarplantar erythrodysesthesia associated with continuous 5-fluorouracil infusion","volume":"8","author":"Fabian","year":"1990","journal-title":"Invest New Drugs"},{"key":"10.3816\/CCC.2006.n.039_bib36","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1517\/14740338.4.6.1005","article-title":"Celecoxib and cardiovascular risks","volume":"4","author":"Brophy","year":"2005","journal-title":"Expert Opin Drug Saf"},{"key":"10.3816\/CCC.2006.n.039_bib37","doi-asserted-by":"crossref","first-page":"813","DOI":"10.7326\/0003-4819-120-9-199405010-00025","article-title":"5-Fluorouracil dermatitis prophylaxis with a nicotine patch","volume":"120","author":"Kingsley","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.3816\/CCC.2006.n.039_bib38","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.breast.2004.12.005","article-title":"Reduced dose capecitabine is an effective and well-tolerated treatment in patients with metastatic breast cancer","volume":"14","author":"El-Helw","year":"2005","journal-title":"Breast"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002811702869?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002811702869?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:59:26Z","timestamp":1761519566000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002811702869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["S1533002811702869"],"URL":"https:\/\/doi.org\/10.3816\/ccc.2006.n.039","relation":{},"ISSN":["1533-0028"],"issn-type":[{"value":"1533-0028","type":"print"}],"subject":[],"published":{"date-parts":[[2006,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hand-Foot Syndrome Variant in a Dihydropyrimidine Dehydrogenase\u2013Deficient Patient Treated with Capecitabine","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CCC.2006.n.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}